|
||||
![]() “The Chapman-KGI School of BioPharmacy will embrace this change in the profession,” said Sheldon Schuster, president and professor of biochemistry at Keck Graduate Institute. “Current advances in genomics and the growing convergence of therapeutics, diagnostics and medical devices are creating new opportunities for pharmacists in the life-sciences industry and modern clinical practice. This new school will help prepare highly qualified individuals to take advantage of those opportunities.” Chapman plans to redesign its Doctor of Pharmacy degree program once the school is open, to focus on new breakthroughs in the field of pharmacogenomics. Students will be exposed to a range of new developments in the industry, learning about personalized medicine, biomolecules and the progression of clinical trials affecting their work. Graduating students will gain understanding of applied life sciences and modern healthcare practice, and experience with therapeutics, therapy management and regulatory affairs. “This collaboration is a remarkable opportunity,” said Jim Doti, president of Chapman University. “It builds on KGI’s innovative professional master’s and postdoctoral programs and close biotechnology and pharmaceutical industry ties, and takes advantage of Chapman’s strengths in computational sciences and entrepreneurship.” Classes will begin on the KGI campus, while construction on a 120,000-square-foot Science Center begins in Orange, which will be home to the Chapman part of the School of BioPharmacy, as well as the Schmid College of Science and Technology. Chapman and KGI have embarked on a national search for a founding dean with pharmacy education and industry experience. Related headlines Chapman gears up for third annual Tomorrow’s Leaders Chapman unveils plans for Filmmakers’ Village Chapman University launches eVillage for startups |
||||